Posted On: 12/17/2015 1:28:17 PM
Post# of 72440
Real information!
http://www.marketwired.com/AdvancedSearch/Adv...96c8479530
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article
BEVERLY, MA --(Marketwired - December 17, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provi...
12/17/2015 11:15:58 AM
Cellceutix First Annual Shareholder Meeting December 15, 2015
BEVERLY, MA --(Marketwired - December 14, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today remin...
12/14/2015 7:30:00 AM
Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
BEVERLY, MA --(Marketwired - December 11, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to in...
12/11/2015 9:18:34 AM
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA --(Marketwired - December 01, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an...
12/1/2015 10:31:56 AM
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
BEVERLY, MA --(Marketwired - November 30, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today...
11/30/2015 7:30:00 AM
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
BEVERLY, MA --(Marketwired - November 25, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an...
11/25/2015 8:00:00 AM
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA --(Marketwired - November 23, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an...
11/23/2015 7:30:00 AM
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
BEVERLY, MA --(Marketwired - November 16, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports th...
11/16/2015 7:30:00 AM
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
BEVERLY, MA --(Marketwired - November 11, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to re...
11/11/2015 10:34:21 AM
Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
BEVERLY, MA --(Marketwired - November 10, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its qu...
11/10/2015 10:51:02 AM
http://www.marketwired.com/AdvancedSearch/Adv...96c8479530
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article
BEVERLY, MA --(Marketwired - December 17, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provi... 12/17/2015 11:15:58 AM
Cellceutix First Annual Shareholder Meeting December 15, 2015
BEVERLY, MA --(Marketwired - December 14, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today remin... 12/14/2015 7:30:00 AM
Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
BEVERLY, MA --(Marketwired - December 11, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to in... 12/11/2015 9:18:34 AM
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA --(Marketwired - December 01, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an... 12/1/2015 10:31:56 AM
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
BEVERLY, MA --(Marketwired - November 30, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today... 11/30/2015 7:30:00 AM
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
BEVERLY, MA --(Marketwired - November 25, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an... 11/25/2015 8:00:00 AM
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA --(Marketwired - November 23, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to an... 11/23/2015 7:30:00 AM
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
BEVERLY, MA --(Marketwired - November 16, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports th... 11/16/2015 7:30:00 AM
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
BEVERLY, MA --(Marketwired - November 11, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to re... 11/11/2015 10:34:21 AM
Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
BEVERLY, MA --(Marketwired - November 10, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its qu... 11/10/2015 10:51:02 AM
(0)
(0)
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!
Scroll down for more posts ▼
